Biotech Values

[mcbio]

Agreed. The possibility that SVR24 might not be the universally accepted efficacy metric for all-oral regimens complicates things immensely from an investment standpoint. Assuming that ABT’s result in #msg-74608528 was not a fluke, I predict that it will take a while before all this gets sorted out.

Have to wonder if it's going to end up where a nuke+PI+NS5A HCV cocktail will ultimately be necessary in IFN and ribavirin-free HCV treatment regimens.